Available compounds per November 2024
–
| Drug | Target genes |
| Axitinib | KDR, FLT4 |
| Crizotinib | ALK, MET, MST1R, ROS1 |
| Dacomitinib | EGFR, HER2, HER4 |
| Erdafitinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Lorlatinib | ALK, ROS1 |
| Niraparib | BRCA1, BRCA2, RAD51C, RAD51D, PALB2, HRD-signature |
| Olaparib | ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L |
| Panitumumab | RAF/RAS wildtype |
| Sunitinib | CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET |
| Talazoparib | ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, RABAC1 (PRA1), HRD signature |
Onderstaand een overzicht van de geopende cohorten. Indien een geschikte patiënt zich voordoet die niet in een van deze cohorten past, kan er in overleg met het studieteam een nieuw cohort geopend worden.
| Drug | Tumor type | Target | Status |
| Abemaciclib | Esophageal | CCND3 amp | Closed |
| Abemaciclib | Astrocytoma | CCND1 amp | Closed |
| Abemaciclib | Carcinoma of the small intestine | CCND3amp | Closed |
| Abemaciclib | Carcinoma of the small intestine | CDK4 amp | Closed |
| Abemaciclib | CRC | CCND1 amp | Closed |
| Abemaciclib | Esophageal | CCND3 amp | Closed |
| Abemaciclib | Glioblastoma | CDK4 amp | Closed |
| Abemaciclib | HNSCC | CCND1 amp | Closed |
| Abemaciclib | Melanoma | CCND1 amp | Closed |
| Abemaciclib | Melanoma | CDK4 amp | Closed |
| Abemaciclib | NSCLC | CCND1 amp | Closed |
| Abemaciclib | NSCLC | CDK4ampl | Closed |
| Abemaciclib | Ovarian | CCND1 amp | Closed |
| Abemaciclib | Prostate | CCND1 amp | Closed |
| Abemaciclib | Sarcoma | CDK4 amp | Closed |
| Abemaciclib | SCC bladder | CCND1 amp | Closed |
| Abemaciclib | Tumor agnostic cohort for CCND3ampl tumors (no CNS tumors) | CCND3amp | Closed |
| Abemaciclib | Urachal cancer | CCND1 amp | Closed |
| Abemaciclib | Urinary tract | CCND1 amp | Closed |
| Abemaciclib | Tumor agnostic cohort for CCND2amp tumors (no CNS tumors) | CCND2amp | Closed |
| Abemaciclib | Tumor agnostic cohort for CDK4 ampl tumors (no CNS tumors) | CDK4ampl | Closed |
| Abemaciclib | Tumor agnostic cohort for patients with CCND1 amplification (no CNS tumors) | CCND1amp | Closed |
| Afatinib | NSCLC | NRG1 fusion | Closed |
| Alectinib | Tumor-agnostic | ALK fusion | Closed |
| Alectinib | Tumor-agnostic | ALK mut/amp | Closed |
| Alpelisib | Anal cancer | PIK3R2 mut | Closed |
| Alpelisib | Cholangiocarcinoma | PTENloss | Closed |
| Alpelisib | GIST | PTEN loss | Closed |
| Alpelisib | Gynaecological PCC | PIK3CA mut | Closed |
| Alpelisib | Gynaecological SCC | PIK3CA mut | Closed |
| Alpelisib | Gynaecological tumors | AKT1 mut | Closed |
| Alpelisib | Gynaecological tumors | PTEN loss | Closed |
| Alpelisib | HNSCC | PIK3Ca mut | Closed |
| Alpelisib | Miscellaneous tumors | PIK3CA mut | Closed |
| Alpelisib | Prostate | PIK3CA mut | Closed |
| Alpelisib | Prostate | PTEN loss | Closed |
| Alpelisib | Radiation associated sarcoma/sarcomatoid carcinoom | PTENloss | Closed |
| Alpelisib | Renal cell | PTEN loss | Closed |
| Alpelisib | Salivary gland | PTEN loss | Closed |
| Alpelisib | Schildkliercarcinoom | PTEN loss | Closed |
| Alpelisib | Speekselkliercarcinoom | PIK3R1 | Closed |
| Alpelisib | Tumor-agnostic | Double hit | Closed |
| Alpelisib | Upper-GI | PIK3CA mut | Closed |
| Atezolizumab + bevacizumab | Tumor-agnostic | TMB ≥16 mut/Mb | Closed |
| Axitinib | CRC | FLT1 amp | Closed |
| Axitinib | Solitary fibrous tumor | KDR mut | Open |
| Cabozantinib | Esophageal | MET mut | Closed |
| Cabozantinib | Esophageal | RET mut | Closed |
| Cabozantinib | GIST | NTRK2 mut | Closed |
| Cabozantinib | Melanoma | MET amp | Closed |
| Cabozantinib | NSCLC | Ret fusion | Closed |
| Cabozantinib | NSCLC | MET mut | Closed |
| Cabozantinib | Teratoma | MET amp | Closed |
| Crizotinib | ACUP | ALK fusion | Open |
| Crizotinib | Biliary tract | ALK mut | Open |
| Crizotinib | Colorectal | ALK mut | Open |
| Crizotinib | Colorectal | MET amp | Open |
| Crizotinib | Esophageal | MET amp | Open |
| Crizotinib | Esophageal | ALK fusion | Open |
| Crizotinib | Gastric | MET amp | Open |
| Crizotinib | Gynaecological tumors | MET amp | Open |
| Crizotinib | Hepatocellular | MET amp | Open |
| Crizotinib | Inflammatory myofibroblastic tumor | ALK fusion | Open |
| Crizotinib | NSCLC | MET mut | Closed |
| Crizotinib | NSCLC | MET amp | Open |
| Crizotinib | NSCLC | MET fusion | Open |
| Crizotinib | Pancreascarcinoom | ROS1 fusion | Open |
| Crizotinib | Renal cell | MET mut | Open |
| Crizotinib | Sarcoma | ALK | Open |
| Crizotinib | Thyroid | ALK mut | Open |
| Crizotinib | Thyroid | MET amp | Open |
| Crizotinib | Thyroid | MET fusion | Open |
| Dabrafenib | Glioblastoma | BRAF V600 mut | Closed |
| Dabrafenib | Urinary tract | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Biliary tract | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | GIST | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Glioblastoma | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Glioma (grade 3) | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Hairy Cell Leukemia | BRAF mut | Closed |
| Dabrafenib + trametinib | Low grade glioma | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Mamma | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Neuroendocrine carcinoma colon | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | NSCLC | BRAF V600 mut | Closed |
| Dabrafenib + trametinib | Pancreas | BRAFmut | Closed |
| Dacomitinib | Ampullary cancer | HER2ampl | Open |
| Dacomitinib | Biliary tract | EGFR ampl | Open |
| Dacomitinib | Breast | HER2 mut | Open |
| Dacomitinib | Cervix | HER2 mut | Open |
| Dacomitinib | Colorectal | EGFR amp | Open |
| Dacomitinib | Colorectal | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 mut | Open |
| Dacomitinib | Esophageal | HER2 amp | Open |
| Dacomitinib | Esophageal | EGFR ampl | Open |
| Dacomitinib | Gastric carcinoma | HER2 amp | Open |
| Dacomitinib | Glioblastoma | EGFR mut | Open |
| Dacomitinib | Gastro-esophageal junction | HER2 amp | Open |
| Dacomitinib | NEC | HER2 mut | Open |
| Dacomitinib | Neurofibromatosis | HER2 mut | Open |
| Dacomitinib | Pancreascarcinoom | HER2 amp | Open |
| Dacomitinib | Penile | HER2 fusion | Open |
| Dacomitinib | Penile | EGFR amp | Open |
| Dacomitinib | Stomach cancer | HER2 amp | Open |
| Dacomitinib | Thyroid cancer | EGFR ampl | Open |
| Dacomitinib | Triple negative breast cancer | EGFR ampl | Open |
| Dacomitinib | UCC | HER2 mut | Open |
| Dacomitinib | Urinary tract | EGFR amp | Open |
| Dacomitinib | Vagina | HER2 mut | Open |
| Dacomitinib | Vulvar | EGFR ampl | Open |
| Durvalumab | Tumor-agnostic | MSI | Closed |
| Entrectinib | Tumor-agnostic | ROS1 fusion | Closed |
| Erdafitinib | Ameloblastoom | FGFR2mut | Open |
| Erdafitinib | Bijnierschorcarcinoom | FGFR3ampl | Open |
| Erdafitinib | Breast | FGFR1amp | Open |
| Erdafitinib | Cholangiocarcinoma | FGFR2 mut | Open |
| Erdafitinib | Cholangiocarcinoma | FGFR2 fusion | Open |
| Erdafitinib | CRC | FGFR1ampl | Open |
| Erdafitinib | CUP | FGFR1ampl | Open |
| Erdafitinib | Endometrial | FGFR1 ampl | Open |
| Erdafitinib | NSCLC | FGFR1ampl | Open |
| Erdafitinib | Ovarian | FGFR1ampl | Open |
| Erdafitinib | Pancreas | FGFR3ampl | Open |
| Erdafitinib | Plexus choroidea carcinoma | FGFR2ampl | Open |
| Erdafitinib | Porocarcinoom | FGFR1ampl | Open |
| Erdafitinib | Prostate | FGFR3ampl | Open |
| Erdaftinib | NSCLC | FGFR3 fusion | Open |
| Erlotinib | Anaplastic astrocytoma | EGFR mut | Closed |
| Erlotinib | CRC | EGFR mut | Closed |
| Erlotinib | Glioblastoma | EGFR fusion | Closed |
| Erlotinib | Glioblastoma | EGFR mut | Closed |
| Lenvatinib | ACUP | FGFR2 fusion | Closed |
| Lenvatinib | Adenoid cystic carcinoma | FGFR2 mut | Closed |
| Lenvatinib | Ameloblastoma | FGFR2 mut | Closed |
| Lenvatinib | Anal cancer | FGFR3 mut | Closed |
| Lenvatinib | Anaplastic thyroid | FGFR3 mut | Closed |
| Lenvatinib | Biliary tract | FGFR2 fusion | Closed |
| Lenvatinib | Biliary tract | FGFR3 fusion | Closed |
| Lenvatinib | Biliary tract | FGFR2 mut | Closed |
| Lenvatinib | Biliary tract | FGFR3 mut | Closed |
| Lenvatinib | Breast | FGFR1 amp | Closed |
| Lenvatinib | Breast | FGFR2 amp/mut | Closed |
| Lenvatinib | Cervix | FGFR3 mut | Closed |
| Lenvatinib | Colorectal | FGFR1 amp | Closed |
| Lenvatinib | Colorectal | FGFR2 amp | Closed |
| Lenvatinib | Endometrial | FGFR2 mut | Closed |
| Lenvatinib | Endometrial | FGFR3 amp | Closed |
| Lenvatinib | Esophageal | FGFR2 amp | Closed |
| Lenvatinib | Glioblastoma | FGFR3 fusion | Closed |
| Lenvatinib | Glioblastoma | FGFR3 mut | Closed |
| Lenvatinib | Glioma | FGFR1 mut | Closed |
| Lenvatinib | Glioneural tumor | FGFR1 mut | Closed |
| Lenvatinib | HNSCC | FGFR3 mut | Closed |
| Lenvatinib | Neuroendocrine nasal cavity | FGFR3 amp | Closed |
| Lenvatinib | NSCLC | FGFR1 amp | Closed |
| Lenvatinib | NSCLC | FGFR2 amp | Closed |
| Lenvatinib | NSCLC | FGFR3 mut | Closed |
| Lenvatinib | Osteosarcoma | FGFR1 amp | Closed |
| Lenvatinib | Pancreas | FGFR1 amp | Closed |
| Lenvatinib | Pancreas | FGFR2 fusion | Closed |
| Lenvatinib | Papillary cancer | FGFR2 mut | Closed |
| Lenvatinib | Salivary duct | FGFR2 mut | Closed |
| Lenvatinib | Salivary gland | FGFR3 amp | Closed |
| Lenvatinib | Sarcoma | FGFR3 fusion | Closed |
| Lenvatinib | Urachal cancer | FGFR2 amp | Closed |
| Lenvatinib | Urinary tract | FGFR3 mut | Closed |
| Lenvatinib | Vagina | FGFR3 mut | Closed |
| Lorlatinib | Cutaneous adnexal carcinoma | ROS-1 amp | Open |
| Lorlatinib | Inflammatory myofibrolastic tumor | ALK fusion | Open |
| Lorlatinib | Mesenchymal tumor | ROS1 fusion | Open |
| Lorlatinib | NSCLC | ROS1 fusion | Open |
| Nilotinib | Colorectal | PDGFRB amp | Closed |
| Nilotinib | Germ cell | KIT mut | Closed |
| Nilotinib | GIST | KIT mut | Closed |
| Nilotinib | GIST | PDGFRA mut | Closed |
| Nilotinib | Melanoma | KIT mut | Closed |
| Nilotinib | Mesothelioma | PDGFRA mut | Closed |
| Niraparib | All other tumor types | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | Lung cancer | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | MPM | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | Primairy brain tumors | HRR alterations (i.e. BRCA1/2, RAD51C, RAD51D, PALB2) | Open |
| Niraparib | Tumor-agnostic | HRD | Open |
| Nivolumab | Tumor-agnostic | MSI (2nd stage) | Closed |
| Nivolumab | Tumor-agnostic | MSI (3rd stage) | Closed |
| Nivolumab | Tumor-agnostic | HML >450 | Closed |
| Nivolumab + ipilimumab | Tumor-agnostic | HML 200-1000 | Closed |
| Olaparib | Tumor-agnostic | BRCA mut/loss | Closed |
| Olaparib | Tumor-agnostic | ATM mut/loss | Closed |
| Olaparib | Tumor-agnostic | Other HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) | Closed |
| Olaparib | Tumor-agnostic | Other HRR alterations (all other tumor types) | Open |
| Palbociclib | (uvual) melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Astrocytoma | CDK4 amp | Closed |
| Palbociclib | Biliary tract | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | SMARCA4 mut | Closed |
| Palbociclib | Colorectal | CCND2 amp | Closed |
| Palbociclib | Colorectal | CDKN2A loss/mut | Closed |
| Palbociclib | Duodenal | CDKN2A loss/mut | Closed |
| Palbociclib | Endometrial carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDK4 amp | Closed |
| Palbociclib | Esophageal | CDKN2A loss/mut | Closed |
| Palbociclib | Glioblastoma | CDKN2A loss/mut | Closed |
| Palbociclib | HNSCC | CDKN2A loss/mut | Closed |
| Palbociclib | Melanoma | CCND1 amp | Closed |
| Palbociclib | Melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CCND1 amp | Closed |
| Palbociclib | NSCLC | CCND1 amp | Closed |
| Palbociclib | NSCLC | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | SMARCA4 mut | Closed |
| Palbociclib | Pancreas | CDKN2A loss/mut | Closed |
| Palbociclib | PECoom | CDK4 amp | Closed |
| Palbociclib | Primitive Neuro-ectodermal tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Prostate | CDK4 amp | Closed |
| Palbociclib | Prostate | CDK6 amp | Closed |
| Palbociclib | Renal cell | CDKN2A loss/mut | Closed |
| Palbociclib | Sarcoma | CDK4 amp | Closed |
| Palbociclib | Vulva carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Vulva carcinoma | CCND1 amp | Closed |
| Panitumumab | (uvual) melanoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | ACUP | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Anal cancer | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Cervix | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Endometrial | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Glioblastoma | BRAF-KRAS-NRAS wildtype | Closed |
| Panitumumab | Gynaecological SCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | HNSCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Meningioma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | NSCLC | BRAF-KRAS-NRAS wildtype + EGFR mut/amp | Open |
| Panitumumab | Salivary duct | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Sarcoma | BRAF-KRAS-NRAS wildtype | On hold |
| Panitumumab | Thyroid | BRAF-KRAS-NRAS wildtype | Open |
| Pembrolizumab | Breast | HML 140-290 | Closed |
| Pembrolizumab | Colorectal | HML 140-290 | Closed |
| Pembrolizumab | HNSCC | HML 140-290 | Closed |
| Pembrolizumab | Miscellaneous tumors | HML 140-290 | Closed |
| Pembrolizumab | Prostate | HML 140-290 | Closed |
| Pembrolizumab | Tumor-agnostic | HML > 290 | Closed |
| Pembrolizumab | Upper-GI | HML 140-290 | Closed |
| Regorafenib | Adenoid cystic carcinoma | BRAF mut | Closed |
| Regorafenib | Duodenal | FLT1 amp | Closed |
| Regorafenib | Esthesioneuroblastoma | RET | Closed |
| Regorafenib | Melanoma | KIT mut | Closed |
| Regorafenib | NSCLC | RAF1 mut | Closed |
| Regorafenib | NSCLC | RET | Closed |
| Regorafenib | Thymus | KIT mut | Closed |
| Ribociclib | ACUP | CDKN2A loss/mut | Closed |
| Ribociclib | Anaplastic meningeoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ceruminous adenocarcinoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ependymoma | CDKN2A loss/mut | Closed |
| Ribociclib | Gastric cancer | CDKN2A loss/mut | Closed |
| Ribociclib | Melanoma | CDK4 amp | Closed |
| Ribociclib | Mesothelioma | CDKN2A loss/mut | Closed |
| Ribociclib | Mucoepidermoid | CDK6 amp | Closed |
| Ribociclib | Prostate | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary gland | CDKN2A loss/mut | Closed |
| Ribociclib | Sarcoma | CDKN2A loss/mut | Closed |
| Ribociclib | Thymus | CDKN2A loss/mut | Closed |
| Ribociclib | Urinary tract | CDKN2A loss/mut | Closed |
| Rucaparib | Breast | HRR alterations | Closed |
| Rucaparib | Miscellaneous tumors | HRR alterations | Closed |
| Rucaparib | Ovarian | HRR alterations | Closed |
| Rucaparib | Pancreas | HRR alterations | Closed |
| Rucaparib | Prostate | HRR alterations | Closed |
| Sunitinb | NSCLC | FGFR1 ampl | Open |
| Sunitinib | Adenoid cystic carcinoma | PDGFRA amp | Open |
| Sunitinib | Breast | PDGFRB amp | Open |
| Sunitinib | Breast cancer | FLT3 ampl | Open |
| Sunitinib | carcinosarcoma uterus | PDGFRA ampl | Open |
| Sunitinib | Colorectal | CSF1R mut | Open |
| Sunitinib | Colorectal | FLT3 amp | Open |
| Sunitinib | NSCLC | KIT amp | Open |
| Sunitinib | Osteosarcoma | PDFGRB mut | Open |
| Sunitinib | Ovarian | FGFR1 amp | Open |
| Sunitinib | Ovarian | FGFR2 amp | Open |
| Sunitinib | Pancreas | RET fusion | Open |
| Sunitinib | Prostate | KITmut | Open |
| Sunitinib | Prostate | PDFGRA mut | Open |
| Sunitinib | Prostate | KIT mut | Open |
| Sunitinib | Pseudomyxoma peritonei | FLT3 mut | Open |
| Sunitinib | Pseudomyxoma peritonei (PMP) | KIT mut | Open |
| Sunitinib | Thymus | KIT mut | Open |
| Sunitinib | Thyroid cancer | PDGFRB mut | Open |
| Sunitinib | Thyroid cancer | PDGFRA mut | Open |
| Sunitinib | Tumor-agnostic | Multi-hit | Open |
| Sunitinib | Urinary tract | FGFR1 amp | Open |
| Talazoparib | Tumor-agnostic | ATM/ATR alteraties | Open |
| Talazoparib | Tumor-agnostic | HRD signature | Open |
| Talazoparib | Tumor-agnostic | FANCA/FANCC/FANCD2/FANCF/FANC mut | Open |
| Talazoparib | Tumor-agnostic | other mutations in HRR genes (BARD1/BRIP1/CHECK1/2/PALB2/RABAC1(PRA1)) | Open |
| Trametinib | (Pilocytic) astrocytoma | BRAF fusion | Closed |
| Trametinib | ACUP | MAP3K1mut | Closed |
| Trametinib | Breast | MAP3K1 mut | Closed |
| Trametinib | Breast | MAP2K4 mut | Closed |
| Trametinib | Cervix | MAP3K1mut | Closed |
| Trametinib | Cholangiocarcinoma | MAP2K4 mut | Closed |
| Trametinib | Colorectal | MAP2K4 mut | Closed |
| Trametinib | Colorectal | MAP2K1 mut | Closed |
| Trametinib | Glioneural tumor | BRAF fusion | Closed |
| Trametinib | Histiocytair sarcoma | MAP2K1mut | Closed |
| Trametinib | Melanocytic tumor | GNA11 mut | Closed |
| Trametinib | Neuroendocrine carcinoma | MAP3K1 mut | Closed |
| Trametinib | Neuroendocrine carcinoma | NRAS mut | Closed |
| Trametinib | NSCLC | BRAF mut | Closed |
| Trametinib | NSCLC | BRAF fusion | Closed |
| Trametinib | NSCLC | MAP2K1 mut | Closed |
| Trametinib | NSCLC | NRAS mut | Closed |
| Trametinib | Ovarian | MAP2K4 mut | Closed |
| Trametinib | Ovarian | BRAF fusion | Closed |
| Trametinib | Ovarian | NRAS mut | Closed |
| Trametinib | Pancreas | MAP2K4 mut | Closed |
| Trametinib | Pancreas | BRAF fusie | Closed |
| Trametinib | Pleimorph tumor | NRAS mut | Closed |
| Trametinib | Prostate | MAP3K1 mut | Closed |
| Trametinib | Prostate | NRAS mut | Closed |
| Trametinib | Salivary duct | BRAF fusion | Closed |
| Trametinib | Salivary duct | NRAS mut | Closed |
| Trametinib | Thyroid | NRAS mut | Closed |
| Trametinib | Tumor-agnostic | GNAS mut | Closed |
| Trametinib | Tumor-agnostic | NF1 mut | Closed |
| Trametinib | Tumor-agnostic | MAP2K1 mut | Closed |
| Trametinib | Urethral carcinoma | NRAS mut | Closed |
| Trametinib | Urinary tract | BRAF fusion | Closed |
| Trametinib | Yolk sac tumor | NRAS mut | Closed |
| Trametinib | Cholangiocarcinoma | NRASmut | Closed |
| Trametinib | Tumor-agnostic | NRASmut | Closed |
| Trastuzumab + pertuzumab | Adenoid cystic carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Biliary tract | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Cervix | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Cervix | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Colorectal | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Colorectal | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Duodenal | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Eccrien carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Eccrien carcinoom | HER2 mutatie | Closed |
| Trastuzumab + pertuzumab | Goblet Cell Carcinoma | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Hidradenocarcinoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Melanoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Neuroendocrine carcinoma | HER2 amp | Closed |
| Trastuzumab + pertuzumab | NSCLC | HER2 mut | Closed |
| Trastuzumab + pertuzumab | NSCLC | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Salivary duct | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Urinary tract | HER2 amp | Closed |
| Trastuzumab + pertuzumab | Urinary tract | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Vulva | HER2 amp | Closed |
| Vemurafenib + cobimetinib | ACUP | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Biliary tract | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Erdheim Chester Disease | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | NSCLC | BRAF non-V600 mut | Closed |
| Vemurafenib + cobimetinib | Ovarian | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Papillair craniopharyngeoma | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Prostate | BRAF non-V600 mut | Closed |
| Vemurafenib + cobimetinib | Salivary duct | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Sarcoma | BRAF V600 mut | Closed |
| Vemurafenib + cobimetinib | Thyroid | BRAF V600 mut | Closed |
| Vismodegib | CNS tumors | PTCH1 mut | Closed |
| Vismodegib | Sarcoma | PTCH1 mut | Closed |